Hepatitis B virus-specific T-cell responses during IFN administration in a small cohort of chronic hepatitis B patients under nucleos(t)ide analogue treatment

Journal of Viral Hepatitis

Volumn 21, Issue 9, 2014, Pages 633-641

  Sprinzl, M F ^a,b   Russo, C ^a   Kittner, J ^b   Allgayer, S ^a   Grambihler, A ^b   Bartsch, B ^b   Weinmann, A ^b   Galle, P R ^b   Schuchmann, M ^b   Protzer, U ^a   Bauer, T ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

hepatitis B surface antigen; immune response; interferon; seroconversion; tumour necrosis factor

Indexed keywords

ADEFOVIR; AMINOTRANSFERASE; CD4 ANTIGEN; CD8 ANTIGEN; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON ALPHA2A; TENOFOVIR; TUMOR NECROSIS FACTOR ALPHA; ALPHA INTERFERON; ANTIVIRUS AGENT; HEPATITIS B CORE ANTIGEN;

ADD ON THERAPY; ADULT; AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ISOLATION; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG WITHDRAWAL; ENZYME ACTIVITY; EX VIVO STUDY; FEMALE; FLOW CYTOMETRY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SEROCONVERSION; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VIRUS LOAD; BLOOD; HEPATITIS B, CHRONIC; IMMUNOLOGY; MIDDLE AGED;

ADULT; ANTIVIRAL AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; FEMALE; FLOW CYTOMETRY; HEPATITIS B CORE ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; TRANSAMINASES;

EID: 84905483843     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12189     Document Type: Article

References (24)

1. Dienstag JL, Goldin RD, Heathcote EJ, et al,. Histological outcome during long-term lamivudine therapy. Gastroenterology [Clinical Trial Randomized Controlled Trial Research Support, Non-U.S. Gov't] 2003; 124 (1): 105-117.
2. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al,. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology [Randomized Controlled Trial] 2006; 131 (6): 1743-1751.
3. Liaw YF, Sung JJ, Chow WC, et al,. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med [Clinical Trial Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't] 2004; 351 (15): 1521-1531.
4. Fattovich G, Giustina G, Sanchez-Tapias J, et al,. Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. European Concerted Action on Viral Hepatitis (EUROHEP). Am J Gastroenterol [Research Support, Non-U.S. Gov't] 1998; 93 (6): 896-900.
5. Kittner JM, Sprinzl MF, Grambihler A, et al,. Adding pegylated interferon to a current nucleos(t)ide therapy leads to HBsAg seroconversion in a subgroup of patients with chronic hepatitis B. J Clin Virol 2012; 54 (1): 93-95.
6. Boni C, Laccabue D, Lampertico P, et al,. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues. Gastroenterology 2012; 143 (4): 963-73 e9.
7. Micco L, Peppa D, Loggi E, et al,. Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B. J Hepatol 2013; 58 (2): 225-233.
8. van der Molen RG, Sprengers D, Biesta PJ, Kusters JG, Janssen HL,. Favorable effect of adefovir on the number and functionality of myeloid dendritic cells of patients with chronic HBV. Hepatology 2006; 44 (4): 907-914.
9. Evans A, Riva A, Cooksley H, et al,. Programmed death 1 expression during antiviral treatment of chronic hepatitis B: impact of hepatitis B e-antigen seroconversion. Hepatology 2008; 48 (3): 759-769.
10. Bauer T, Sprinzl M, Protzer U,. Immune control of hepatitis B virus. Dig Dis [Research Support, Non-U.S. Gov't Review] 2011; 29 (4): 423-433.
11. Maini MK, Boni C, Lee CK, et al,. The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med [Research Support, Non-U.S. Gov't] 2000; 191 (8): 1269-1280.
12. Bertoletti A, Maini M, Williams R,. Role of hepatitis B virus specific cytotoxic T cells in liver damage and viral control. Antiviral Res 2003; 60 (2): 61-66.
13. Chang JJ, Thompson AJ, Visvanathan K, et al,. The phenotype of hepatitis B virus-specific T cells differ in the liver and blood in chronic hepatitis B virus infection. Hepatology [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't] 2007; 46 (5): 1332-1340.
14. Wherry EJ,. T cell exhaustion. Nat Immunol [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review] 2011; 12 (6): 492-499.
15. Daniels HM, Meager A, Eddleston AL, Alexander GJ, Williams R,. Spontaneous production of tumour necrosis factor alpha and interleukin-1 beta during interferon-alpha treatment of chronic HBV infection. Lancet 1990; 335 (8694): 875-877.
16. Torre D, Zeroli C, Giola M, et al,. Serum levels of interleukin-1 alpha, interleukin-1 beta, interleukin-6, and tumor necrosis factor in patients with acute viral hepatitis. Clin Infect Dis 1994; 18 (2): 194-198.
17. Yoshioka K, Kakumu S, Arao M, et al,. Immunohistochemical studies of intrahepatic tumour necrosis factor alpha in chronic liver disease. J Clin Pathol 1990; 43 (4): 298-302.
18. Larrea E, Garcia N, Qian C, Civeira MP, Prieto J,. Tumor necrosis factor alpha gene expression and the response to interferon in chronic hepatitis C. Hepatology [Research Support, Non-U.S. Gov't] 1996; 23 (2): 210-217.
19. Boni C, Fisicaro P, Valdatta C, et al,. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol [Comparative Study Research Support, Non-U.S. Gov't] 2007; 81 (8): 4215-4225.
20. Ferrari C, Penna A, Bertoletti A, et al,. Cellular immune response to hepatitis B virus-encoded antigens in acute and chronic hepatitis B virus infection. Journal of Immunology [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.] 1990; 145 (10): 3442-3449.
21. Jung MC, Diepolder HM, Spengler U, et al,. Activation of a heterogeneous hepatitis B (HB) core and e antigen-specific CD4 + T-cell population during seroconversion to anti-HBe and anti-HBs in hepatitis B virus infection. J Virol [Research Support, Non-U.S. Gov't] 1995; 69 (6): 3358-3368.
22. Bohne F, Chmielewski M, Ebert G, et al,. T cells redirected against hepatitis B virus surface proteins eliminate infected hepatocytes. Gastroenterology [Research Support, Non-U.S. Gov't] 2008; 134 (1): 239-247.
23. Reijnders JG, Perquin MJ, Zhang N, Hansen BE, Janssen HL,. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B. Gastroenterology 2010; 139 (2): 491-498.
24. Hadziyannis SJ, Sevastianos V, Rapti I, Vassilopoulos D, Hadziyannis E,. Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir. Gastroenterology 2012; 143 (3): 629-636.